Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
CASE REPORT
Extra-articular symptoms spondyloarthropathies for example, a patient with predominant symptoms of ocular treated with a good therapeutic effect of infliximab
Online publication date: 2012-12-21
Reumatologia 2012;50(6):534-537
KEYWORDS
ABSTRACT
Uveitis is a common extra-articular symptom in the course of spondyloarthropathies. Especially when often relapsing, uveitis may lead to serious ocular complications, including complete loss of vision. Due to unsatisfactory results of treatment with synthetic immunosuppressive drugs, TNF inhibitors are being tested.
In this paper we present a brief summary of uveitis therapy with biological compounds and a case of an adult patient with spondyloarthropathy with recurrent uveitis treated successfully with infliximab.
In this paper we present a brief summary of uveitis therapy with biological compounds and a case of an adult patient with spondyloarthropathy with recurrent uveitis treated successfully with infliximab.
REFERENCES (19)
1.
van den Berg R, van der Heijde DM. How should we diagnose spondyloarthritis according to the ASAS classification criteria: guide for practicing physicians. Pol Arch Med Wewn 2010; 120: 452-457.
2.
Van den Bosch F. A survey of European and Canadian rheumatologists regarding the treatment of patients with ankylosing spondylitis and extra-articular manifestations. Clin Rheumatol 2010; 29: 281-288.
3.
Van der Cruyssen B. Extra-articular manifestations in ankylosing spondylitis. Ann Rheum Dis 2007; 66: 1072-1077.
4.
Max R, Lorenz HM, Mackensen F. Ocular involvement in spondyloarthropathies: HLA associated uveitis. Rheumatology 2010; 69: 397-402.
5.
Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-783.
6.
Fernández-Melón J, Mun~oz-Fernández S, Hidalgo V, et al. Uveitis as the initial clinical manifestation in patients with spondyloarthropathies. J Rheum 2004; 31: 524-527.
7.
Paroli MP, Spinucci G, Fabiani C, Pivetti-Pezzi P. Retinal complications of juvenile idiopathic arthritis-related uveitis: a microperimetry and optical coherence tomography study. Ocul Immunol Inflamm 2010; 18: 54-59.
8.
Son JH, Cha SW. Anti-TNF-αlpha therapy for ankylosing spondylitis. Clin Orthop Surg 2010; 2: 28-33.
9.
Cervantes-Castaneda RA, Bhat PV, Huynh N, et al. The role of azathioprine in the treatment of ocular inflammatory disease: a six month follow-up analysis. Program and abstracts of the Association for Research in Vision and Ophthalmology (ARVO) 2008 Annual Meeting; April 27-May 1, 2008; Fort Lauderdale, Florida. Abstract 5822.
10.
Mun~oz-Fernández S, Hidalgo V, Fernández-Melón J, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 2003; 30: 1277-1279.
11.
Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure of intolerance in the treatment of scleritis or uveitis. Arch Ophthalmol 2008; 126: 186-191.
12.
Yu C, Mahdi R, Egwuagu C. Daclizumab (Zenapax) selectively blocks expansion of human Th17, but not Th1 cells. Program and abstracts of the Association for Research in Vision and Ophthalmology (ARVO) 2008 Annual Meeting; April 27-May 1, 2008; Fort Lauderdale, Florida. Abstract 2525.
13.
Quinones K, Bhat P, Foster CS. High dose intravenous methotrexate for the treatment of recalcitrant ocular inflammatory diseases. Program and abstracts of the Association for Research in Vision and Ophthalmology (ARVO) 2008 Annual Meeting; April 27-May 1, 2008; Fort Lauderdale, Florida. Abstract 4740.
14.
Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001; 33: 251-255.
15.
Greiner K, Murphy CC, Willermain F, et al. Anti-TNFαlpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci 2004; 45: 170-176.
16.
McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-158.
17.
Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447-2451.
18.
Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006; 65: 1631-1634.
19.
El-Shabrawi Y, Mangge H, Hermann J. Anti-tumour necrosis factor alpha treatment in chronic recurrent inflammation of the anterior segment of the eye in patients resistant to standard immu¬nomodulatory treatment. Ann Rheum Dis 2003; 62: 1243-1244.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
